Research Type: Extramural
Professor David Watkins and his team have discovered a previously unknown reason for treatment resistance in lung cancer.
This research project will use a powerful microscope to identify how tumour cells activate T cells, a type of immune cell.
This project will evaluate the impact of improved chronic hepatitis C (HCV) treatment on liver cancer incidence and survival.
This study will explore whether certain microRNAS could be targeted in combination with chemotherapy to kill breast cancer cells and improve patient outcomes.
This research builds on previous findings that the protein MCL-1 acts like a life and death switch for triple negative breast cancer cells.
This project will determine how drug resistance develops at the genetic level and explore ways of making treatment approaches more effective.
Developing a world first radiation system to ensure the safe delivery of radiation doses to patients
This team is perfecting a new radiation dosimetry system that will detect and treat cancers as they move through the body.
This SPAR trial will test whether taking a statin for 3 months during and after cancer treatment improves the response of a rectal tumour to radiation and chemotherapy.
Using models of a bone cancer developed in the lab, Dr Kansara will investigate the effectiveness of targeting a specific immune protein, both alone and in combination with chemotherapy.
This project will provide the critical clinical evidence on the effectiveness of adding progesterone to antiestrogenic therapies in patients with early stage breast cancer.